Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

• US 8,586,720 B2
• Filed: 07/06/2012
• Issued: 11/19/2013
• Est. Priority Date: 11/07/2007
• Status: Active Grant

• Current Assignee: Celldex Therapeutics Incorporated
• Original Assignee: Celldex Therapeutics Incorporated
• Inventors: Keler, Tibor, He, Lizhen, Ramakrishna, Venky, Vitale, Laura A.
• Primary Examiner(s): JUEDES, AMY E
• Application Number:
  US13/542,909
• Publication Number:
  US 20120309031A1
• Time in Patent Office: 501 Days
• Field of Search: None
• US Class Current: 536/23.53
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 : Antimycotics
• CPC Class Codes: A61P 31/12 : Antivirals
• CPC Class Codes: A61P 31/14 : for RNA viruses
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 31/20 : for DNA viruses
• CPC Class Codes: A61P 33/00 : Antiparasitic agents
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 : Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/14 : of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/40 : Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/08 : Vasodilators for multiple indications
• CPC Class Codes: C07K 16/2851 : against the lectin superfamily, e.g. CD23, CD72
• CPC Class Codes: C07K 2317/21 : from primates, e.g. man
• CPC Class Codes: C07K 2317/77 : Internalization into the cell
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide

Abstract

Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Claims

1. An isolated nucleic acid encoding antibody heavy and light chain variable regions which bind human DEC-205 (SEQ ID NO:

1) comprising CDR1, CDR2, and CDR3 amino acid sequences as follows;

(a) a heavy chain variable region CDR1 comprising SEQ ID NO;

29;

a heavy chain variable region CDR2 comprising SEQ ID NO;

30;

a heavy chain variable region CDR3 comprising SEQ ID NO;

31;

a light chain variable region CDR1 comprising SEQ ID NO;

35;

a light chain variable region CDR2 comprising SEQ ID NO;

36; and

a light chain variable region CDR3 comprising SEQ ID NO;

37;

(b) a heavy chain variable region CDR1 comprising SEQ ID NO;

17;

a heavy chain variable region CDR2 comprising SEQ ID NO;

18;

a heavy chain variable region CDR3 comprising SEQ ID NO;

19;

a light chain variable region CDR1 comprising SEQ ID NO;

23;

a light chain variable region CDR2 comprising SEQ ID NO;

24; and

a light chain variable region CDR3 comprising SEQ ID NO;

25;

(c) a heavy chain variable region CDR1 comprising SEQ ID NO;

5;

a heavy chain variable region CDR2 comprising SEQ ID NO;

6;

a heavy chain variable region CDR3 comprising SEQ ID NO;

7;

a light chain variable region CDR1 comprising SEQ ID NO;

11;

a light chain variable region CDR2 comprising SEQ ID NO;

12; and

a light chain variable region CDR3 comprising SEQ ID NO;

13;

(d) a heavy chain variable region CDR1 comprising SEQ ID NO;

41;

a heavy chain variable region CDR2 comprising SEQ ID NO;

42;

a heavy chain variable region CDR3 comprising SEQ ID NO;

43;

a light chain variable region CDR1 comprising SEQ ID NO;

47;

a light chain variable region CDR2 comprising SEQ ID NO;

48; and

a light chain variable region CDR3 comprising SEQ ID NO;

49;

(e) a heavy chain variable region CDR1 comprising SEQ ID NO;

53;

a heavy chain variable region CDR2 comprising SEQ ID NO;

54;

a heavy chain variable region CDR3 comprising SEQ ID NO;

55;

a light chain variable region CDR1 comprising SEQ ID NO;

59;

a light chain variable region CDR2 comprising SEQ ID NO;

60; and

a light chain variable region CDR3 comprising SEQ ID NO;

61;

or

(f) a heavy chain variable region CDR1 comprising SEQ ID NO;

77;

a heavy chain variable region CDR2 comprising SEQ ID NO;

78;

a heavy chain variable region CDR3 comprising SEQ ID NO;

79;

a light chain variable region CDR1 comprising SEQ ID NO;

83;

a light chain variable region CDR2 comprising SEQ ID NO;

84; and

a light chain variable region CDR3 comprising SEQ ID NO;

85.

2. An expression vector comprising the nucleic acid of claim 1.

3. A cell transformed with the expression vector of claim 2.

4. An isolated nucleic acid encoding antibody heavy and light chain variable regions comprising amino acid sequences as set forth in:

(a) SEQ ID NOs;

28 and 34;

(b) SEQ ID NOs;

4 and 10;

(c) SEQ ID NOs;

16 and 22;

(d) SEQ ID NOs;

40 and 46;

(e) SEQ ID NOs;

52 and 58;

or

(f) SEQ ID NOs;

76 and 82.

5. An expression vector comprising the nucleic acid of claim 4.

6. A cell transformed with the expression vector of claim 5.